H.C. Wainwright reiterates Brainsway stock rating on IPMG deal
H.C. Wainwright reiterated a Buy rating and $19.00 price target on Brainsway (BWAY) following its partnership with Inland Psychiatric Medical Group. The stock has a 68% upside potential from its current price of $11.99. Brainsway reported Q2 2026 revenue of $17.1M, beating estimates, and raised its full-year revenue guidance to $68M-$70M, citing strong demand for its Deep TMS systems.
How this was made
The 30-second read
Why it matters
Analyst reiteration and partnership provide a fresh catalyst that could lift the stock, though scale is limited.
Market read
The news is a primary disclosure of a new strategic partnership and analyst rating upgrade for a micro‑cap medical device maker.
What to watch
Potential reimbursement challenges and competition from alternative neuromodulation therapies could temper growth.
Background
Brainsway reported Q2 2026 results earlier, but the new IPMG collaboration and analyst rating change constitute fresh news.
Ticker impact
H.C. Wainwright reiterated a Buy rating and raised the price target to $19 after Brainsway announced a strategic collaboration with Inland Psychiatric Medical Group (IPMG).
likely upward pressure as investors price in expanded sales pipeline
Analyst upgrade plus a concrete multi‑system order provides a tangible revenue catalyst; however, the company remains a micro‑cap with limited liquidity.
Market effects
May boost broader interventional psychiatry and TMS equipment sector as other providers see increased demand.
Strengthens healthcare technology exposure in Southern California and could influence regional biotech/medtech indices.
Limited to niche mental‑health device market; minimal global impact.
Counterpoint
The partnership size may be modest and execution risk high; the price target could be overly optimistic for a micro‑cap.
Key entities
- CompanyBrainsway Ltd.
Developer of Deep TMS systems for psychiatric treatment.
- CompanyInland Psychiatric Medical Group
Behavioral health provider in Southern California.
- Research FirmH.C. Wainwright
Equity research firm that issued the rating.
